6-乙炔喹噁啉 | 442517-33-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6-乙炔喹噁啉
• 英文名称: 6-ethynylquinoxaline
• CAS: 442517-33-1
• 化学式: C₁₀H₆N₂
• 分子量: 154.171
• InChiKey: QSYDWUWZZBZOCD-UHFFFAOYSA-N

物化性质

• 熔点：
  98 °C
• 沸点：
  285.8±20.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-乙炔喹噁啉 在 copper(l) iodide 、 四(三苯基膦)钯 、 四甲基乙二胺 、 叠氮基三甲基硅烷 、 potassium carbonate 作用下， 以 四氢呋喃 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.0h， 生成 4-[4-(6-Methyl-pyridin-2-yl)-5-quinoxalin-6-yl-[1,2,3]triazol-2-yl]-benzonitrile
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor

  摘要：

  A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Compound 8d showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 muM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38alpha MAP kinase inhibition (13%) at a concentration of 10 muM that is much lower than that of SB-431542 (54%). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.024
• 作为产物：
  描述：

  6-溴喹喔啉 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 15.0h， 生成 6-乙炔喹噁啉
  参考文献：
  名称：

  Design, synthesis, and evaluation of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives as Aurora kinase inhibitors

  摘要：

  A series of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives were designed, synthesized, and evaluated for the Aurora kinase inhibitory activities. The novel hinge-binder tethered 1,2,3-triazolylsalicylamide scaffold was effectively assembled by Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC). A variety of alkynes with hinge binders were used to search proper structures-binding relationship to the hinge region. The synthesized 1,2,3-triazolylsalicylamide derivatives showed significant Aurora kinase inhibitory activity. In particular, 8a inhibited Aurora A kinase with an IC50 value of 0.284 mu M, whereas 8m inhibited Aurora B kinase with an IC50 value of 0.364 mu M. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.03.042

文献信息

• [EN] TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT<br/>[FR] IMIDAZOLES TRI-SUBSTITUÉS POUR L'INHIBITION DE TGF-BÊTA ET MÉTHODES DE TRAITEMENT
  申请人：CLAVIUS PHARMACEUTICALS LLC

  公开号：WO2019005241A1

  公开（公告）日：2019-01-03

  Pharmaceutical compounds, their methods of manufacture, and methods of treatment of mammals with pharmaceutical compounds are provided.

  提供了药物化合物、其制造方法以及使用药物化合物治疗哺乳动物的方法。
• Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same
  申请人：Fujimura Osamu

  公开号：US20090091243A1

  公开（公告）日：2009-04-09

  The present invention provides a substituted ethynyl gold-nitrogen containing heterocyclic carbene complex represented by the general formula (1): wherein L represents a nitrogen containing heterocyclic carbene ligand; and X represents an alkyl group, a cycloalkyl group, an aryl group, an aralkyl group or a heterocyclic group; in which one or more hydrogen atoms on the carbon atom(s) of X may be replaced by a halogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, a dialkylamino group, an acyl group or an arylcarbonyl group; and, when more than one hydrogen atom on the carbon atom(s) of X is replaced by the alkyl group, the alkenyl group, the aryl group, the aralkyl group, the alkoxy group, the aryloxy group, the dialkylamino group, the acyl group or the arylcarbonyl group, the adjacent groups may be bonded together to form a ring, a method for preparing the same, and an organic electroluminescent device comprising the substituted ethynyl gold-nitrogen containing heterocyclic carbene complex in at least one organic compound thin layer.

  本发明提供了一种置换的乙炔基金属-氮杂环卡宾配合物，其通式表示为（1）：其中L代表含氮杂环卡宾配体；X代表烷基、环烷基、芳基、芳基烷基或杂环基；其中X的碳原子上的一个或多个氢原子可以被卤素原子、烷基、环烷基、烯基、芳基、芳基烷基、烷氧基、芳氧基、二烷基氨基、酰基或芳基羰基所取代；当X的碳原子上有多个氢原子被烷基、烯基、芳基、芳基烷基、烷氧基、芳氧基、二烷基氨基、酰基或芳基羰基所取代时，相邻的基团可以结合形成环；本发明还提供了一种制备该配合物的方法，以及包含该置换的乙炔基金属-氮杂环卡宾配合物的至少一个有机化合物薄层的有机电致发光器件。
• NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS)
  申请人：GALAPAGOS NV

  公开号：US20160039807A1

  公开（公告）日：2016-02-11

  A compound according to Formula (Ia), wherein Cy, L 1 , G, and R 1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

  根据公式（Ia）描述的化合物，其中Cy，L1，G和R1如本文所述。本发明涉及一种新的化合物，其按照公式（I）拮抗GPR84，一种参与炎症状况的G蛋白偶联受体，并提供制备这些新化合物的方法，包括这些化合物的制药组合物，以及通过给予本发明化合物预防和/或治疗炎症状况（例如炎症性肠病（IBD），类风湿性关节炎，血管炎），肺部疾病（例如慢性阻塞性肺疾病（COPD）和肺间质性疾病（例如特发性肺纤维化（IPF））），神经炎症性状况，感染性疾病，自身免疫性疾病，内分泌和/或代谢性疾病，和/或通过给予本发明化合物来改善免疫细胞功能的疾病。
• Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment
  申请人：CLAVIUS PHARMACEUTICALS, LLC

  公开号：US11124509B2

  公开（公告）日：2021-09-21

  Pharmaceutical compounds, their methods of manufacture, and methods of treatment of mammals with pharmaceutical compounds are provided.

  提供了药物化合物、其制造方法以及用药物化合物治疗哺乳动物的方法。
• WO2019241461A5
  申请人：——

  公开号：WO2019241461A5

  公开（公告）日：2022-01-14